Atrys 1H FY26 EBITDA climbs 21.3% to EUR 9.3 million; revenue rises 9.4% to EUR 77.7 million

Reuters2026/09/10 06:24

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Atrys posted H1 2026 revenue of EUR 77.7 million, up 9.4% from a year earlier; EBITDA rose 21.3% to EUR 9.3 million.
Operating cash flow climbed to EUR 7.2 million, up 191.5%, reflecting higher EBITDA and streamlined investment of EUR 2.1 million.
Net financial debt fell 79.2% to EUR 35.4 million after the January ASPY sale; financial expenses dropped by EUR 4.4 million.
Oncology revenue rose 22.5% to EUR 37.1 million; Nuclear Medicine EBITDA more than doubled on strong performance in Portugal.
Guidance reaffirmed for 2026: revenue EUR 156.5 million, up 11%; reported EBITDA EUR 20.5 million, up 40%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atrys Health SA published the original content used to generate this news brief on September 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Atrys 1H FY26 EBITDA climbs 21.3% to EUR 9.3 million; revenue rises 9.4% to EUR 77.7 million

You may also like

Crypto prices